TRT Monitoring Schedule: Your Year-One Lab Timeline

A TRT monitoring schedule is the routine of lab tests and provider check-ins used across your first year on testosterone therapy to check how you are responding and to identify side effects early. Most men who start care for low testosterone want to know how often they will need bloodwork and what those labs are actually looking for. Monitoring is heaviest early on, then settles into a steadier rhythm once levels hold stable.

Clinical guidelines lay out a clear arc for that first year, and a telehealth provider builds its protocols around it. This guide walks through the year-one timeline stage by stage, the specific labs on a standard TRT monitoring schedule, and what happens when a result needs a closer look.

What Is a TRT Monitoring Schedule?

A TRT monitoring schedule is a planned series of blood tests and clinical reviews that track how your body responds to testosterone therapy. It checks hormone levels, blood counts, and prostate and cardiovascular markers at set points, starting before treatment and continuing through the first year and beyond (Bhasin et al., 2018; Mulhall et al., 2018).

The aim is not a single target number. Guidelines stress that treatment decisions rest on symptoms and confirmed deficiency together, not on a lab value in isolation (Mulhall et al., 2018). A monitoring schedule gives your provider repeated snapshots so the dose can be matched to your response and any side effect can be addressed early. The same framework applies whether you are learning the basics of hormone lab testing at the start or you are already months into a protocol.

Why Ongoing Labs Matter on Testosterone Therapy

Testosterone therapy treats a diagnosed deficiency, but raising hormone levels shifts other markers that need watching. In February 2025, the FDA updated labeling across all testosterone products. It removed the older boxed warning about cardiovascular risk and added a warning about blood pressure increases. Testosterone is approved for hypogonadism due to a medical condition, and because the labeling and indications continue to evolve, your provider can advise on current status (FDA, 2025).

That label change followed the TRAVERSE trial, which studied 5,246 men with hypogonadism and cardiovascular risk. It did not find a higher rate of major adverse cardiac events on testosterone compared with placebo, but it did record more atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group (Lincoff et al., 2023). Those mixed signals are why blood pressure and cardiovascular health stay on the schedule rather than being checked once and dropped.

Blood counts matter too. Higher testosterone can raise hematocrit, the share of red blood cells in your blood. A 2025 study found that a meaningful share of patients on testosterone therapy developed a rising hematocrit over time, which is why it is monitored (Neidhart et al., 2025). A high hematocrit is a common reason a provider may adjust the dose, which is why it is checked regularly.

Your Year-One TRT Monitoring Timeline

Guidelines map testosterone monitoring to a predictable first-year arc, from a baseline workup before treatment, to close early follow-up after starting, a stability check once levels settle, and periodic testing after that (Bhasin et al., 2018; Mulhall et al., 2018). The table below summarizes a standard TRT monitoring schedule, and the sections that follow explain each stage.

Before You Start: Baseline Labs

Monitoring begins before the first dose. Guidelines call for confirming low testosterone with repeat early-morning blood draws, since levels peak in the morning and vary day to day, and for pairing that result with symptoms before any treatment starts. There is no single universal cut-off, so the threshold is interpreted by your provider and the guideline they follow (Mulhall et al., 2018).

A baseline panel typically includes hematocrit and, for older men or those at higher risk, a PSA check before starting (Mulhall et al., 2018). Your provider reviews these baseline results first and may delay or adjust treatment if a value is already high, as part of an individualized plan. Comparing symptoms and lab results at this stage helps set realistic expectations, because a result that looks normal on paper does not always match how a person feels.

The Early Follow-Up Window

This is the most active monitoring window. The Endocrine Society recommends an early evaluation after starting, including testosterone and hematocrit, with the exact timing depending on the formulation (Bhasin et al., 2018). Prostate monitoring with PSA, and a digital rectal exam where appropriate, is a shared decision with your provider based on age and personal risk rather than a fixed schedule (Bhasin et al., 2018).

Symptom response tracks its own timeline. Research on the onset of testosterone effects describes changes in sexual interest in the early weeks and shifts in body composition over the following months, with several effects still building well beyond (Saad et al., 2011). Early labs confirm the dose is moving levels in the right direction while symptoms catch up.

Once Levels Are Stable

Once levels are stable, monitoring spaces out. The AUA recommends measuring testosterone periodically once a man is stable on therapy, alongside hematocrit checks as indicated (Mulhall et al., 2018). This is where your provider confirms the response is holding and reviews whether the formulation and dose still fit.

After the First Year

After the first year, most guidelines move to periodic testing of testosterone, hematocrit, and the prostate, with more frequent checks only if a result or symptom calls for it (Bhasin et al., 2018; Mulhall et al., 2018). Recent data adds a caveat. Testosterone-related rises in hematocrit do not only appear early, but ongoing checks also stay relevant well beyond the first year (Neidhart et al., 2025).

Which Labs Are on a TRT Monitoring Schedule?

A standard panel covers hormone levels, blood counts, prostate markers, and cardiovascular markers. Total and free testosterone show whether the dose is reaching the intended level, and SHBG and albumin help interpret the results when they look unexpected (Bhasin et al., 2018).

Hematocrit tracks red blood cell concentration and flags erythrocytosis, the buildup that raises clotting risk. PSA supports prostate surveillance, framed by individual risk rather than a fixed rule (Mulhall et al., 2018). Blood pressure is tracked routinely after the FDA's 2025 labeling warning (FDA, 2025). Estradiol is not required by the core guidelines but is often added in practice, and estradiol monitoring becomes relevant when symptoms point to it.

What If a Result Comes Back Too High?

An abnormal result usually leads to a change in the plan rather than ending therapy. The most common example is hematocrit. A high hematocrit may prompt your provider to pause therapy, check for contributing causes such as sleep apnea, and adjust the dose, with therapeutic phlebotomy used in some cases (Bhasin et al., 2018; Mulhall et al., 2018).

Other findings have their own responses. A rising PSA prompts closer prostate evaluation rather than an automatic stop. Side effects like acne, fluid retention, or breast tissue changes that can occur when some testosterone converts to estrogen are managed case by case. If a result concerns you, talk with your provider before changing anything rather than stopping on your own. These findings are exactly what scheduled labs exist to catch, under a provider's direction and based on your results.

How Formulation Changes the Monitoring Plan

The testosterone formulation affects when labs are drawn, because each one peaks and clears differently. Injections of testosterone cypionate or enanthate produce peaks and troughs, so timing the draw matters; transdermal gels and creams give steadier daily levels; and pellets release slowly over months (Bhasin et al., 2018). The differences between creams versus injections shape both the dosing rhythm and the monitoring rhythm.

Product type matters here. FDA-approved testosterone products exist for diagnosed hypogonadism, and a specific approved product can be described as FDA-approved for that use. Compounded testosterone is not FDA-approved and should not be treated as equivalent to an approved product. Which formulation you receive is set by your provider based on your evaluation.

Fertility Planning During the First Year

Fertility deserves its own conversation early. Testosterone therapy suppresses the body's own production and can lower sperm output. This effect varies between men and often recovers after stopping, but recovery is not certain, so men planning to have children should raise it before starting (Mulhall et al., 2018).

Maintaining fertility on therapy is more straightforward when the conversation happens before the first dose, and fertility preservation is part of what a provider weighs at intake. Options such as hCG or alternative protocols are easier to plan when raised early rather than after suppression has set in.

Telehealth and Your TRT Monitoring Schedule

Telehealth makes consistent monitoring practical, since labs can be ordered locally and reviewed remotely. Testosterone is a Schedule III controlled substance, so it requires evaluation by a licensed clinician and is prescribed only when medically appropriate, with lab confirmation and where state law permits. A temporary federal flexibility allows online prescribing of controlled substances without an initial in-person visit; this flexibility is set to expire and may change, and state law still varies.

What stays constant is the schedule itself. Whether through a TRT program or in-person care, a sound TRT monitoring schedule follows the same year-one arc, from baseline through early follow-up, a stability check once levels settle, and periodic testing thereafter, with the timing and labs set by your provider and your results rather than a fixed formula (Bhasin et al., 2018; Mulhall et al., 2018).

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

How often do you need labs on a TRT monitoring schedule?

Monitoring is most frequent early, then spaces out. The Endocrine Society recommends an early check of testosterone and hematocrit after starting, then periodically, while the AUA recommends measuring testosterone periodically once a man is stable. Your provider sets the exact timing based on your formulation and response.

What labs are included in the first year of TRT?

A standard first-year panel covers testosterone (total and often free), hematocrit, and prostate monitoring with PSA, plus blood pressure after the FDA's 2025 labeling update. Estradiol is added in some protocols when symptoms suggest it. The exact mix depends on your history and provider evaluation.

How often should hematocrit be checked on testosterone therapy?

Guidelines recommend hematocrit at baseline, again early in treatment, and then periodically, with extra checks if it climbs. This matters because a 2025 study of patients on testosterone therapy found that a meaningful share developed a rising hematocrit over time. A high hematocrit usually prompts a dose change or other steps.

Does a TRT monitoring schedule include prostate (PSA) checks?

Yes. Guidelines recommend PSA and, where appropriate, a digital rectal exam at baseline and early in treatment, framed as a shared decision with your provider based on age and personal risk. Major guideline panels note there is no clear evidence that testosterone therapy causes prostate cancer, though prostate surveillance stays part of the plan.

Can testosterone therapy raise blood pressure?

It can, which is why blood pressure is monitored. In February 2025 the FDA added a warning about blood pressure increases to all testosterone product labeling, based on ambulatory blood pressure data. Your provider tracks it alongside your other markers.

Does TRT affect fertility, and is that part of monitoring?

Testosterone therapy suppresses natural production and can lower sperm output. This effect varies between men and often recovers after stopping, but recovery is not certain, so men planning to have children should discuss it before starting. Options such as hCG or alternative protocols are easier to plan early.

References

• Eur J Endocrinol. 2011;165(5):675-685.

• Front Endocrinol (Lausanne). 2025;15:1496906.

• J Clin Endocrinol Metab. 2018;103(5):1715-1744.

• J Urol. 2018;200(2):423-432.

• N Engl J Med. 2023;389(2):107-117.

• U.S. Food and Drug Administration. Class-wide labeling changes for testosterone products. 2025.